Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Economic Evaluation of New MDR-TB Regimens (PRACTECAL-EE)
NCT04207112Phase 3Completed
- Sponsor
- Médecins Sans Frontières
- Start
- Oct 2020
- Primary completion
- Aug 2022
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of pretomanid in multidrug-resistant tuberculosis (MDR-TB), sponsored by Médecins Sans Frontières. Started Oct 2020; status: completed.
02
Drugs
pretomanid
03
Conditions
multidrug-resistant tuberculosis (MDR-TB)
Beyond the preview
Go deeper on NCT04207112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04207112.